去甲基化药物在急性髓细胞白血病中的应用

金洁; 凌清

doi:10.13201/j.issn.1004-2806.2024.05.004

去甲基化药物在急性髓细胞白血病中的应用

金洁^1, ,,
凌清¹

- 浙江大学医学院附属第一医院血液科(杭州，310003)

详细信息

作者简介:
专家简介：金洁，医学博士，浙江大学二级教授、主任医师、博士生导师，享受国务院特殊津贴。全国三八红旗手、全国卫生系统先进工作者、浙江大学好医生。现任浙江大学医学院附属一院血液科名誉主任、学科带头人，浙江省血液肿瘤(诊治)重点实验室主任，国家卫建委临床重点学科-血液病学科带头人，浙江省血液病临床医学研究中心主任，浙江大学癌症研究院恶性血液病基础与临床研究团队负责人。中国女医师协会血液肿瘤专委会主任委员、CSCO抗白血病联盟副主任委员、CSCO抗淋巴瘤联盟常务委员、中国抗癌协会整合血液病副主任委员、中国医师协会血液病医师分会常务委员、海峡两岸血液病专委会常务委员、浙江省医师协会血液病分会会长、中国抗癌协会血液病转化专委会名誉主任委员。以第一完成人获得2011年国家科技进步二等奖1项、浙江省科学技术进步奖一等奖2项、二等奖4项。以第一与通讯作者(共同)在Lancet Oncol，Cell，JCO，Blood，Leukemia，JHO等国际期刊上发表SCI论文170余篇

通讯作者: 金洁, E-mail: jiej0503@zju.edu.cn

中图分类号: R733.71

收稿日期: 2024-03-15

刊出日期: 2024-05-01

The application of demethylating drugs in acute myeloid leukemia

JIN Jie^1, ,,
LING Qing¹

- Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China

More Information

Corresponding author: JIN Jie, E-mail: jiej0503@zju.edu.cn

Received Date: 15 March 2024

Publish Date: 01 May 2024

摘要

摘要: 急性髓细胞白血病(acute myeloid leukemia，AML)是一类起源于造血干细胞的恶性克隆性血液系统疾病，以造血干细胞的分化受阻和异常增殖为主要特征，是成人白血病中最常见的类型。2020年一项关于全球负担的研究进一步阐述了AML在全球范围内的疾病负担，揭示了其对人口健康的广泛影响。AML的治疗历经多年发展，不断涌现出新的治疗策略和药物。AML包括异常DNA甲基化模式，进而导致整体低甲基化和局部高甲基化，这两者均促进了AML的发病。因此在其治疗策略不断演进中引入了去甲基化药物，去甲基化药物通过改变肿瘤细胞的基因表达模式，促进肿瘤细胞的分化凋亡，已成为AML治疗的重要组成部分，标志着治疗方法向着更为精准的方向发展。
- 急性髓细胞白血病 /
- 去甲基化药物 /
- 治疗
Abstract: Acute myeloid leukemia(AML) is a kind of malignant clonal hematological disease originated from hematopoietic stem cells. It is characterized by impaired differentiation and abnormal proliferation of hematopoietic stem cells. It is the most common type of adult leukemia. A study on the global burden in 2020 further elaborated the disease burden of AML worldwide and revealed its extensive impact on population health. A large number of new treatment strategies and drugs have constantly emerged after years of development. AML includes abnormal DNA methylation pattern, which leads to global hypomethylation and local hypermethylation, both of which promote the pathogenesis of AML. Therefore, demethylated drugs have been introduced into the treatment strategy. Demethylated drugs have become an important part of AML treatment by changing the gene expression mode of tumor cells and promoting the differentiation and death of tumor cells, marking the development of treatment methods towards a more accurate direction.
- acute myeloid leukemia /
- demethylated drugs /
- treatment

HTML全文

参考文献(24)

[1]	Yi M, Li A, Zhou L, et al. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017[J]. J Hematol Oncol, 2020, 13(1): 72. doi: 10.1186/s13045-020-00908-z
[2]	Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia[J]. Adv Cancer Res, 1998, 72: 141-196.
[3]	Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses[J]. Cell, 2015, 162(5): 974-986. doi: 10.1016/j.cell.2015.07.011
[4]	Mayyas IM, Weeks RJ, Day RC, et al. Hairpin-bisulfite sequencing of cells exposed to decitabine documents the process of DNA demethylation[J]. Epigenetics, 2021, 16(11): 1251-1259. doi: 10.1080/15592294.2020.1861169
[5]	Issa JP, Kantarjian HM, Kirkpatrick P. Azacitidine[J]. Nat Rev Drug Discov, 2005, 4(4): 275-276. doi: 10.1038/nrd1698
[6]	Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with>30% blasts[J]. Blood, 2015, 126(3): 291-299. doi: 10.1182/blood-2015-01-621664
[7]	Wei AH, Döhner H, Pocock C, et al. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission[J]. N Engl J Med, 2020, 383(26): 2526-2537. doi: 10.1056/NEJMoa2004444
[8]	Cojutti PG, Pea F. Azacitidine for Acute Myeloid Leukemia: Why One Dose Does Not Fit All[J]. Clin Pharmacol Ther, 2024, 115(3): 403. doi: 10.1002/cpt.3154
[9]	Rivard GE, Momparler RL, Demers J, et al. Phase Ⅰ study on 5-aza-2'-deoxycytidine in children with acute leukemia[J]. Leuk Res, 1981, 5(6): 453-462. doi: 10.1016/0145-2126(81)90116-8
[10]	Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase Ⅲ trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia[J]. J Clin Oncol, 2012, 30(21): 2670-2677. doi: 10.1200/JCO.2011.38.9429
[11]	Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia[J]. Leuk Lymphoma, 2013, 54(9): 2003-2007. doi: 10.3109/10428194.2012.762093
[12]	Bhatnagar B, Duong VH, Gourdin TS, et al. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy[J]. Leuk Lymphoma, 2014, 55(7): 1533-1537. doi: 10.3109/10428194.2013.856425
[13]	Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes[J]. N Engl J Med, 2016, 375(21): 2023-2036. doi: 10.1056/NEJMoa1605949
[14]	DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study[J]. Lancet Oncol, 2018, 19(2): 216-228. doi: 10.1016/S1470-2045(18)30010-X
[15]	DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia[J]. Blood, 2019, 133(1): 7-17. doi: 10.1182/blood-2018-08-868752
[16]	Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia[J]. N Engl J Med, 2022, 386(16): 1519-1531. doi: 10.1056/NEJMoa2117344
[17]	Venugopal S, Takahashi K, Daver N, et al. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy[J]. Blood Cancer J, 2022, 12(1): 10. doi: 10.1038/s41408-021-00604-2
[18]	Short NJ, DiNardo CD, Daver N, et al. A triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia: results from a phase Ⅰ/Ⅱ study[J]. Blood, 2021, 138: 696. doi: 10.1182/blood-2021-153571
[19]	Jin H, Zhang Y, Yu S, et al. Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial[J]. J Hematol Oncol, 2023, 16(1): 42. doi: 10.1186/s13045-023-01437-1
[20]	DiNardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial[J]. Lancet Haematol, 2020, 7(10): e724-e736. doi: 10.1016/S2352-3026(20)30210-6
[21]	Kim K, Maiti A, Loghavi S, et al. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax[J]. Cancer, 2021, 127(20): 3772-3781. doi: 10.1002/cncr.33689
[22]	Maiti A, DiNardo CD, Daver NG, et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia[J]. Blood Cancer J, 2021, 11(2): 25. doi: 10.1038/s41408-021-00410-w
[23]	Savona MR, Odenike O, Amrein PC, et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study[J]. Lancet Haematol, 2019, 6(4): e194-e203. doi: 10.1016/S2352-3026(19)30030-4
[24]	Ceccarelli V, Valentini V, Ronchetti S, et al. Eicosapentaenoic acid induces DNA demethylation in carcinoma cells through a TET1-dependent mechanism[J]. FASEB J, 2018, 32: 5990-6001. doi: 10.1096/fj.201800245R